JPRN-jRCTs031220219
Recruiting
Phase 2
A Feasibility Study of definitive radiotherapy using 60Gy with FOLFOX for Unresectable Esophageal Cancer
Miura Akinori0 sites20 target enrollmentJuly 20, 2022
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Esophageal cancer
- Sponsor
- Miura Akinori
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Histologically diagnosed squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma by endoscopic biopsy of the primary esophageal tumor.
- •2\) CT images show that the tumor is unresectable.
- •That is, one of the following applies
- •i. Wall depth of the primary tumor is T4
- •ii. Involvement of other organs via regional lymph node metastasis
- •iii. Progression after preoperative or induction chemotherapy that meets i\-ii above
- •3\) No distant organ metastasis on CT imaging, except for lymph node metastasis in the supraclavicular fossa if the primary lesion is in the upper chest, lymph node metastasis in either the supraclavicular fossa or periclavicular lymph nodes if the primary lesion is in the mid\-thoracic region, or lymph node metastasis in the periclavicular lymph nodes if the primary lesion is in the lower chest.
- •4\) Age is 18 years or older.
- •5\) ECOG PS less than or equal to 2
- •6\) No previous radical surgery for esophageal cancer except for endoscopic submucosal dissection
Exclusion Criteria
- •1\) Have active multiple cancers (concurrent multiple cancers and heterogeneous multiple cancers with a disease\-free interval of 3 years or less). However, lesions equivalent to intraepithelial or intramucosal carcinoma that are considered curable by local treatment are not included in active multiple carcinoma.
- •2\) Patients with poorly controlled diabetes mellitus.
- •3\) Patients with poorly controlled hypertension
- •4\) Patients with any of the following conditions requiring treatment: coronary artery disease, cardiomyopathy, heart failure, and arrhythmia.
- •5\) Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema
- •6\) Patients with active infections
- •7\) Pregnant or potentially pregnant women, and lactating women
- •8\) Patients with concomitant psychiatric disorders or psychiatric symptoms who are judged by the pri
- •ncipal investigator or sub\-investigator to be unable to participate in the study
- •9\) Patients who are deemed unsuitable for participation in the study by the investigators for any other reason.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
A pilot study of definitive chemoradiotherapy using involved-field intensity-modulatd radiation therapy for patients with clinical stage IB-IIIC (non T4) esophageal carcinomaEsophageal neoplasmJPRN-UMIN000017668Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University12
Completed
N/A
Investigating the protocols for radiotherapy to the breast: an evaluation of treatment morbidity, accuracy and efficiencyBreast cancerCancerMalignant neoplasm of breastISRCTN34017998HS R&D Regional Programme Register - Department of Health (UK)
Active, Not Recruiting
N/A
Phase II study of definitive radiochemotherapy for locally advanced squamous cell cancer of the vulva: an efficacy study - radiotherapy for vulvar canceradvanced stage squamous cell cancer of the vulvaMedDRA version: 8.1Level: LLTClassification code 10047777Term: Vulvar cancerEUCTR2006-004052-20-NLKoningin Wilhelmina Fonds
Completed
Phase 2
Phase II study of definitive radiochemotherapy for locally advanced squamous cell cancer of the vulva: an efficacy studyvulvar cancervulvar neoplasm1003859710029903NL-OMON30199Academisch Medisch Centrum68
Recruiting
N/A
Prospective observational study of radiotherapy with respiratory migration countermeasures for breast cancerJPRN-UMIN000045576Kagawa University Hospital30